Phase 1
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.
The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them.
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine in an early-stage clinical trial. They published their work in the journal Nature Medicine.
San Francisco-based Audentes Therapeutics signed a licensing agreement and collaboration deal with Nationwide Children’s Hospital to expand its pipeline for vectorized antisense treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
The latest job cuts at Merrimack come about five months after the company culled 60 percent of its staff.
According to the NIH, the experimental vaccine is designed to “teach the body to make protective immune responses against diverse influenza subtypes by focusing the immune system on a portion of the virus that varies relatively little from strain to strain.”
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
Good safety profile and encouraging efficacy reported for recurrent glioblastoma patients with disrupted blood-brain barrier
PRESS RELEASES